BENIGN PROSTATIC HYPERPLASIA. Enlarged prostate
Conditions
Interventions
Intervention 1: The group receiving a dose of 10 mg tadalafil from Farabi Pharmaceuticals daily for 12 weeks, once a day. Intervention 2: The group receiving a dose of 20mg tadalafil from Farabi Pharm
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
45 Years to No maximum
Inclusion criteria
Inclusion criteria: Age more than 45 years Patient satisfaction Having symptoms of Lower Urinary Tract Syndrom( LUTS) for at least 4 weeks Prostate-specific antigen( PSA) lesser than 4 nm Post Void Residual( PVR) volume 300 ml or more Qmax 4 to 15 mL/s of pre-void bladder volume
Exclusion criteria
Exclusion criteria: Lack of consent to participate in the study Severe liver or kidney failure Simultaneous use of nitrates
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Presence or absence of lower urinary tract symptoms. Timepoint: Before starting the medication and after 12 weeks of taking the medication. Method of measurement: checklist. | — |
Secondary
| Measure | Time frame |
|---|---|
| The volume remaining in the bladder after voiding. Timepoint: At the beginning of the study and after twelve weeks of taking tadalafil tablets. Method of measurement: Urodynamic test.;Maximum urine flow( Qmax). Timepoint: At the beginning of the study and after twelve weeks of taking tadalafil tablets. Method of measurement: Urodynamic test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRasool Jafari
Arak University of Medical Sciences
Outcome results
None listed